AGTC-401, AGTC-402 Gene Therapies Well-Tolerated in Achromatopsia


Clinical trials for both AGTC-401 and AGTC-402 show promising results.

This content originallly appeared on our sister site, Ophthalmology Times. Reviewed by Mark E. Pennesi, MD, PhD.

AGTC-401 and AGTC-402 (Applied Genetic Technologies Corporation), subretinal gene therapies for achromatopsia, were seen to be well-tolerated in 2 ongoing phase 1/2 clinical trials.

Marl E. Pennesi, MD, PhD, associate professor of ophthalmology, molecular and medical genetics, Kenneth C. Swan Endowed Professor and division chief, ophthalmic genetics, Oregon Health and Science University’s Casey Eye Institute, stressed that data from both studies are showing encouraging signs of biologic activity.

ACHM is an autosomal recessive disease that causes a cone dysfunction syndrome, with the bulk of the mutations found in 2 genes, CNGA3 and CNGB3.

Two clinical trials of the affected genes are underway. One is a long-term follow-up gene therapy study for achromatopsia CNGB3 and CNGA3, at Moorfields Eye Hospital in London, England, and Kellogg Eye Center in Ann Arbor, Michigan.

The other is a natural history study of achromatopsia CNGB3 and CNGA3, at Moorfields Eye Hospital.

Patients with ACHM have central vision in the range of 20/100 to 20/200, nystagmus, color vision defects, photophobia, and high myopia.

Electroretinography (ERG) shows severely decreased cone function but normal rod function, Pennesi explained. Both trials are phase 1/2, open-label, dose-escalation studies.

The enrolled patients were treated with 1 subretinal injection of either AGTC-401 (rAAV2tYF-PR1.7-hCNGB3; 26 patients) or AGTC-402 (rAAV2tYF-PR1.7-hCNGA3; 19 patients) into the macular region on 1 eye (study eye). All patients were 14 years or older.

Participants were sequentially assigned to 1 of 4 dosing groups in both studies.

The primary end points were changes in the best-corrected visual acuity, light discomfort testing by ocular photosensitivity analyzer, ERG and multifocal ERG, retinal sensitivity by static perimetry and microperimetry, color vision testing using the Farnsworth D15 and color assessment and diagnosis tests, and patient-reported outcomes using the quality-of-life Visual Light Sensitivity Questionnaire-8.

Most ocular adverse events were mild to moderate in nature. Of those that occurred in more than 20% of eyes, the most common was conjunctival hemorrhage, which likely was related to the surgical procedure.

Vitreous and anterior chamber cells were seen more frequently in the ACHM-CNGB3 group.

In the CNGA3 group, 2 patients had a serious adverse event. One was a macular hole related to the study surgery, and the other was ocular hypertension related to the steroids prescribed. It was controlled with modification of the steroids.

One patient in the CNGB3 group had steroid-related increased intraocular pressure that was controlled with modification of the steroids.

The preliminary results also showed improvements in photosensitivity and 2-color dark light-adapted perimetry in 3 of the 16 patients in the CNGA3 study and 7 of the 16 patients in the CNGB3 study in the higher-dose groups.


Mark E. Pennesi, MD, PhD
e:[email protected]
This article is adapted from Pennesi’s presentation at the Association for Research in Vision and Ophthalmology’s 2021 virtual annual meeting. He is a consultant to Applied Genetic Therapies Corporation.

Related Videos
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Shankar Ramaswamy, MD, the cofounder, chairman, and CEO of Kriya Therapeutics
Zheng-Yi Chen, DPhil, on Looking Deeper Into Effects of Gene Therapy on OTOF Deafness
Arshad Khanani, MD
Alfonso Sabater, MD, PhD
Shankar Musunuri, PhD
Ula V. Jurkunas, MD
Alfonso Sabater, MD, PhD, on Bringing Gene Therapy to Ophthalmology
Shankar Musunuri, PhD
© 2024 MJH Life Sciences

All rights reserved.